<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02965716</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2016-01698</org_study_id>
    <secondary_id>NCI-2016-01698</secondary_id>
    <secondary_id>S1607</secondary_id>
    <secondary_id>S1607</secondary_id>
    <secondary_id>S1607</secondary_id>
    <secondary_id>U10CA180888</secondary_id>
    <nct_id>NCT02965716</nct_id>
  </id_info>
  <brief_title>Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma</brief_title>
  <official_title>A Phase II Study of Combining Talimogene Laherparepvec T-VEC (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well talimogene laherparepvec and pembrolizumab work in
      treating patients with stage III-IV melanoma. Biological therapies, such as talimogene
      laherparepvec, use substances made from living organisms that may stimulate or suppress the
      immune system in different ways and stop tumor cells from growing. Monoclonal antibodies,
      such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
      Giving talimogene laherparepvec and pembrolizumab may work better in treating patients with
      melanoma by shrinking the tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the durable response rate of treatment with talimogene laherparepvec (T-VEC)
      in combination with MK-3475 (pembrolizumab) following progression on prior anti-PD-1 or
      anti-PD-L1 therapy alone or in combination with other agents different from T-VEC.

      SECONDARY OBJECTIVES:

      I. To estimate the objective response rate (confirmed and unconfirmed, complete and partial
      responses) in the injected lesions.

      II. To estimate the objective response rate (ORR) in the non-visceral, non-injected lesions.

      III. To estimate the objective response rate (ORR) in the visceral lesions (Cohort A).

      IV. To estimate the overall objective response rate (ORR). V. To estimate the median
      progression-free survival (PFS). VI. To estimate the median overall survival (OS). VII. To
      evaluate the toxicity of the regimen.

      TERTIARY OBJECTIVES:

      I. To evaluate whether adding T-VEC to PD1 blockade can increase T-cell infiltration into
      tumors and whether change in T-cell infiltration is associated with response.

      II. To evaluate whether adding T-VEC to PD1 blockade can increase T-cell receptor (TCR)
      clonality in tumors and in peripheral blood and whether increased TCR clonality is associated
      with response.

      III. To evaluate whether intra-tumoral injection of T-VEC is associated with the tumor immune
      microenvironment.

      IV. To evaluate whether tumor mutational load and mutations in the IFN pathway is associated
      with response to T-VEC plus MK-3475 (pembrolizumab) therapy in the anti-PD1/L1 therapy
      refractory melanoma patients.

      OUTLINE:

      Patients receive talimogene laherparepvec intralesionally (IL) and pembrolizumab
      intravenously (IV) over 30 minutes on day 1. Treatment repeats every 21 days for up to 18
      courses for talimogene laherparepvec and 36 courses for pembrolizumab in the absence of
      disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 6 months for up to 2
      years and then annually for a total of 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2017</start_date>
  <completion_date type="Anticipated">July 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Durable response rate (DRR) defined as complete response (CR) or partial response (PR) with no evidence of disease progression from the initial documentation of CR/PR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Cohort A and B)</measure>
    <time_frame>Up to 180 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate (complete and partial, confirmed and unconfirmed responses) assessed by RECIST1.1 (Cohort A)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be estimated by three different methods. RECIST 1.1 will be applied, but with the following restrictions: 1) considering only the injected lesions as target lesions, 2) considering only the non-injected lesions as target lesions,3) considering only the visceral lesions as target lesions and 4) across all lesions. 95% confidence intervals will be constructed for the estimated rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (Cohort B)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will be estimated in injected lesions, non-injected lesions, across all lesions and construct 95% confidence intervals for the estimated rates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median progression-free survival (Cohort A and B)</measure>
    <time_frame>From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 6 months</time_frame>
    <description>Will construct 95% Brookmeyer-Crowley confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival (Cohort A and B)</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Will construct 95% Brookmeyer-Crowley confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DRR (Cohort A and B)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Will assess the association between durable response rate and CD8 T-cell infiltration in the injected tumors using a two-sample t-test to test for difference in mean quantitative CD8 expression between patients who have a durable response and patients who do not have a durable response. If the distributions are far from normal or subject to influential points, then instead of t-tests, robust, rank based or non-parametric alternatives such as the Wilcoxon test will be used. The analysis will be repeated to assess the association between durable response rate and CD8 T-cell infiltration in the non-injected tumors.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in T-cell infiltration (Cohort A and B)</measure>
    <time_frame>Baseline to week 2</time_frame>
    <description>CD8 expression levels will be compared using a paired t-test. Among patients that progress, the analysis will be repeated to compare CD8 expression at progression to baseline with the understanding that there is potentially informative missingness in that patients who do not progress may have higher infiltration.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in increased T-cell infiltration (Cohort A and B)</measure>
    <time_frame>Baseline to week 2</time_frame>
    <description>Associated with higher DRR. The change in CD8 expression between week 2 and baseline will be computed and compared to the change in CD8 expression between durable responders and non-durable responders using a two-sample t-test at the two-sided 0.05 level.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in T cell receptor (TCR) clonality levels assessed in peripheral blood (Cohort A)</measure>
    <time_frame>Baseline to week 2</time_frame>
    <description>Will compute the clonality metric as the normalized Shannon entropy for all patients at baseline and week 2. The change in clonality metric will be computed and compared between durable responders and non-durable responders using a two-sample t-test with significance determined at the two-sided alpha=0.05 level.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in TCR clonality within tumor assessed in peripheral blood (Cohort B)</measure>
    <time_frame>Baseline to week 2</time_frame>
    <description>Will test for difference in mean normalized Shannon entropy for all patients. The analysis will be repeated to compare TCR clonality at progression to baseline among patients who progress. To assess the hypothesis that TCR clonality is higher in patients who respond to the combination therapy, suggesting that the T-cells are targeting the tumor, the clonality metric will be computed as the normalized Shannon entropy for all patients at baseline and week 2. The change in clonality will be compared between durable responders and non-durable responders using a two-sample t-test with significance determined at the two-sided alpha=0.05 level. The analyses examining TCR clonality in peripheral blood will be repeated.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in tumor microenvironment following talimogene laherparepvec (T-VEC) (Cohort A and B)</measure>
    <time_frame>Baseline to week 2</time_frame>
    <description>Will examine the expression of approximately 10 candidate immune markers: PD-L1, PD-1, dendritic cell markers (CD80, CD86), immune suppressive cell markers (anti-FoxP3 for regulatory T cell [Treg], anti-CD68 antibody for macrophage, clone PG-M1, DAKO, anti-CD14 for monocyte, and CD15 for granulocytes). For each marker, a difference in expression will be tested between baseline and the 2 weeks using paired t-tests at the alpha = 0.005 level to accommodate multiple comparisons. The association between change in expression level of each marker (from baseline to 2 weeks) with response using a two-sample t-test at the alpha = 0.005 level will be tested.</description>
  </other_outcome>
  <other_outcome>
    <measure>T-VEC effect on mutational load (Cohort A and B)</measure>
    <time_frame>Baseline to week 2</time_frame>
    <description>The per megabase mutation rate for each individual will be calculated. Then a paired t-test will be used to compare the mutation rate at 2 weeks to the mutation rate at baseline. To estimate the anticipated power, it is assumed that a paired t-test will be used (although the distribution of mutational load is highly skewed, the change in mutational load may be sufficiently well behaved).</description>
  </other_outcome>
  <other_outcome>
    <measure>Mutational load (Cohort A and B)</measure>
    <time_frame>Baseline to week 2</time_frame>
    <description>Will assess the association between overall mutational load at each time point, separately, and durable response rate. Logistic regression to regress response status on the mutation rates (at baseline or at week 2) and use a 1-df test to obtain a p-value for the association between durable response and mutation rate will be used.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Recurrent Melanoma</condition>
  <condition>Stage III Cutaneous Melanoma AJCC v7</condition>
  <condition>Stage IIIA Cutaneous Melanoma AJCC v7</condition>
  <condition>Stage IIIB Cutaneous Melanoma AJCC v7</condition>
  <condition>Stage IIIC Cutaneous Melanoma AJCC v7</condition>
  <condition>Stage IV Cutaneous Melanoma AJCC v6 and v7</condition>
  <arm_group>
    <arm_group_label>Treatment (talimogene laherparepvec, pembrolizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive talimogene laherparepvec IL and pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 18 courses for talimogene laherparepvec and 36 courses for pembrolizumab in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (talimogene laherparepvec, pembrolizumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (talimogene laherparepvec, pembrolizumab)</arm_group_label>
    <other_name>Keytruda</other_name>
    <other_name>Lambrolizumab</other_name>
    <other_name>MK-3475</other_name>
    <other_name>SCH 900475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Talimogene Laherparepvec</intervention_name>
    <description>Given IL</description>
    <arm_group_label>Treatment (talimogene laherparepvec, pembrolizumab)</arm_group_label>
    <other_name>ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene</other_name>
    <other_name>Imlygic</other_name>
    <other_name>JS1 34.5-hGMCSF 47- pA-</other_name>
    <other_name>T-VEC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have pathologically confirmed stage IV or unresectable stage III
             melanoma; patients must not have disease that is suitable for local therapy,
             administered with curative intent

          -  Patients must have measurable disease per Response Evaluation Criteria in Solid Tumors
             (RECIST) 1.1; contrast-enhanced computed tomography (CT) scans of the neck, chest,
             abdomen and pelvis are required; a whole body positron emission tomography (PET)/CT
             scan with diagnostic quality images and intravenous iodinated contrast may be used in
             lieu of a contrast enhanced CT of the chest, abdomen and pelvis; imaging of the head
             and neck is required only if the patient has a head/neck primary; contrast may be
             omitted if the treating investigator believes that exposure to contrast poses an
             excessive risk to the patient; if skin lesions are being followed as measurable
             disease, photograph with a ruler included and physician measurements, must be kept in
             the patients chart as source documentation; all measurable lesions must be assessed
             within 28 days prior to registration; tests to assess non-measurable disease must be
             performed within 42 days prior to registration; all disease must be assessed and
             documented on the baseline tumor assessment form (RECIST 1.1)

          -  Cohort A: Patients must have at least one measurable visceral lesion (per RECIST 1.1);
             a visceral lesion is any solid organ except for skin, lymph node, and musculoskeletal
             tissue; at least one of these visceral lesions must be measurable per RECIST 1.1

          -  Cohort B: Patients must not have any visceral lesions

          -  Patients must, in the opinion of the treating physician, be candidates for
             intralesional administration into cutaneous, subcutaneous, or nodal lesions; patients
             must have at least 2 injectable lesions

          -  Patients may have brain metastases if all lesions have been treated with stereotactic
             radiation therapy, craniotomy, or gamma knife therapy with no evidence of progression
             (demonstrated by identical imaging modality for 2 consecutive assessments/scans
             [magnetic resonance imaging (MRI) or CT scans], at least 4 weeks apart) and have not
             required steroids for at least 14 days prior to registration

          -  Patient must have had prior treatment with anti-PD-1 or anti-PD-L1 agents and have
             documented disease progression on these agents prior to registration; patient must
             have received anti-PD-1 or PD-L1 based therapy as the immediate previous line of
             treatment and within 56 days prior to registration

          -  Patients must not have had surgery, biologic therapy, or hormonal therapy within 14
             days prior to registration; patients must not have had chemotherapy, targeted small
             molecule therapy, or radiation therapy within 28 days (42 days for nitrosoureas or
             mitomycin C) prior to registration; patients must not have had an investigational
             agent or monoclonal antibodies, except anti-PD1/L1 antibodies, within 28 days prior to
             registration

               -  Patients must have recovered from all adverse events due to prior anti-cancer
                  therapy (residual toxicity â‰¤ grade 1) prior to registration, with the exception
                  of patients with =&lt; grade 2 neuropath or =&lt; grade 2 alopecia

               -  If patients received major surgery, they must have recovered adequately from
                  toxicity and/or complications from the intervention prior to registration

          -  Patients must not have received prior treatment with talimogene laherparepvec (T-VEC)
             or other oncolytic virus agents

          -  Patients must not have received any live vaccine within 30 days prior to registration;
             seasonal flu vaccines that do not contain live virus are permitted

          -  Patients must not be planning to receive other biologic therapy, radiation therapy,
             hormonal therapy, chemotherapy, surgery, or other therapy while on this protocol;
             palliative radiation therapy or surgery can be considered for symptomatic non-target
             lesions after discussions with the study team

          -  Patients must have Zubrod performance status =&lt; 2

          -  Absolute neutrophil count (ANC) &gt;= 1,500/mcL within 28 days prior to registration

          -  Hemoglobin &gt;= 9 g/dL within 28 days prior to registration

          -  Platelets &gt;= 100,000/mcL within 28 days prior to registration

          -  Albumin &gt;= 2.5 g/dL within 28 days prior to registration

          -  Total bilirubin =&lt; 1.5 x institutional upper limit of normal (IULN) except patients
             with documented Gilbert's syndrome within 28 days prior to registration

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both &lt; 2.5 x IULN
             within 28 days prior to registration

          -  Serum creatinine &lt; 2.0 x IULN within 28 days prior to registration

          -  Patients must have prothrombin time (PT) / international normalized ratio (INR) and
             partial thromboplastin time (PTT) =&lt; 2.0 x institutional upper limit of normal (IULN)
             unless the patient is on anticoagulant therapy within 28 days prior to registration
             (if the patient is receiving anticoagulant therapy, PT, and a PTT must be within
             therapeutic range of intended use of anticoagulants)

          -  Activated partial thromboplastin time (aPTT) =&lt; 2.0 x IULN if not using anticoagulants
             within 28 days prior to registration; if using anticoagulants, then the value must be
             within therapeutic range according to the condition for which the patient is being
             treated within 28 days prior to registration

          -  Patients must have lactate dehydrogenase (LDH) obtained prior to registration

          -  Patients must have complete physical examination and medical history obtained within
             28 days prior to registration

          -  Patients must not require use of systemic corticosteroid within 14 days prior to
             registration or during protocol treatment; patients with preexisting severe autoimmune
             disease requiring systemic corticosteroids or ongoing immunosuppression are not
             eligible

          -  Patients must not have known history of hepatitis B, hepatitis C, human
             immunodeficiency virus (HIV); the use of physiologic doses of corticosteroids may be
             approved after consultation with the study chair

          -  Patients must not have history of (non-infectious) pneumonitis that required steroids
             or current pneumonitis

          -  Patients must not have an active infection requiring systemic therapy nor a viral
             infection requiring intermittent treatment with an antiherpetic drug, other than
             intermittent topical use

          -  Patients must not have active herpetic skin lesions or prior complications of herpetic
             infection (e.g., herpetic keratitis or encephalitis) which requires intermittent or
             chronic treatment with an anti-herpetic drug other than intermittent topical use

          -  Patients must not have organ allografts

          -  Patients must not have an uncontrolled intercurrent illness including, but not limited
             to, nonmalignant medical illnesses that are uncontrolled or whose control may be
             jeopardized by the treatment with the study therapy, or psychiatric illness/social
             situations which would limit compliance with study requirements

          -  Patients must not have history or evidence of active autoimmune disease (e.g.,
             pneumonitis, glomerulonephritis, vasculitis, or other); or history of active
             autoimmune disease that has required systemic treatment (i.e., use of corticosteroids,
             immunosuppressive drugs or biological agents used for treatment of autoimmune
             diseases) within 2 months of registration; replacement therapy (e.g., thyroxine for
             hypothyroidism, insulin for diabetes or physiologic corticosteroid replacement therapy
             for adrenal or pituitary insufficiency) is not considered a form of systemic treatment
             for autoimmune disease

          -  Patient must not have evidence of any clinically significant immunosuppression such as
             the following:

               -  Primary immunodeficiency state such as severe combined immunodeficiency disease;

               -  Concurrent opportunistic infection;

               -  Receiving systemic immunosuppressive therapy (&gt; 2 weeks) including oral steroid
                  doses &gt; 10 mg/day of prednisone or equivalent within 2 months prior to enrollment

          -  No other prior malignancy is allowed except for the following: adequately treated
             basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
             stage I or II cancer from which the patient is currently in complete remission, or any
             other cancer from which the patient has been disease free for two years

          -  Patients must not be pregnant or nursing; women of reproductive potential must have a
             negative serum pregnancy test within 7 days prior to registration; women/men of
             reproductive potential must have agreed to use an effective contraceptive method while
             on study and for 120 days after last study treatment; a woman is considered to be of
             &quot;reproductive potential&quot; if she has had menses at any time in the preceding 12
             consecutive months; in addition to routine contraceptive methods, &quot;effective
             contraception&quot; also includes heterosexual celibacy and surgery intended to prevent
             pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,
             bilateral oophorectomy or bilateral tubal ligation; however, if at any point a
             previously celibate patient chooses to become heterosexually active during the time
             period for use of contraceptive measures outlined in the protocol, he/she is
             responsible for beginning contraceptive measures

          -  Patients must be willing to submit blood and tissue specimens for translational
             medicine

          -  Patients must be offered the opportunity to participate in specimen banking for future
             research

          -  Patients must be informed of the investigational nature of this study and must sign
             and give written informed consent in accordance with institutional and federal
             guidelines

          -  As a part of the Oncology Patient Enrollment Network (OPEN) registration process the
             treating institution's identity is provided in order to ensure that the current
             (within 365 days) date of institutional review board approval for this study has been
             entered in the system
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siwen Hu-Lieskovan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southwest Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SWOG</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siwen Hu-Lieskovan</last_name>
      <phone>888-798-0719</phone>
    </contact>
    <investigator>
      <last_name>Siwen Hu-Lieskovan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2016</study_first_submitted>
  <study_first_submitted_qc>November 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2016</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

